Evidence map›Paper›PMID 40787691›Full record

ReviewExpert reviews in molecular medicine2025

The Application of iPSCs in Tumour Immunotherapy.

Peinan Chen, Jian Gao, Jianing Feng, Hongfei Tao, Yongkui Yu, Yijing Li, Jinlong Liu, Shuangshuang Lu, Wei Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert reviews in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peinan ChenDepartment of Thoracic surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Jian GaoNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21Zhengzhou University, Zhengzhou, China.
Jianing FengNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21Zhengzhou University, Zhengzhou, China.
Hongfei TaoNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21Zhengzhou University, Zhengzhou, China.
Yongkui YuDepartment of Thoracic surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Yijing LiNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21Zhengzhou University, Zhengzhou, China.
Jinlong LiuNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21Zhengzhou University, Zhengzhou, China.
Shuangshuang LuNational Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Tianjian Advanced Biomedical Laboratory, Academy of Medical Sciences, https://ror.org/04ypx8c21Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-8144-1830
Wei WangDepartment of Thoracic surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumour immunotherapy holds great promise as a treatment for cancer, which ranks as the second highest cause of mortality worldwide. This therapeutic approach can be broadly categorized into two main types: active immunotherapy and passive or adoptive immunotherapy. Active immunotherapy, such as cancer vaccines, stimulates the patients' immune system to target tumour cells. On the other hand, adoptive immunotherapy involves supplying in vitro activated immune cells, such as T cells, natural killer cells and macrophages, to the patient to combat the tumour. Induced pluripotent stem cells are extensively utilized in both active and adoptive tumour immunotherapy due to their pluripotency and ease of gene editing. They can be differentiated into various types of immune cells for direct cancer treatment and can also function as tumour vaccines to elicit an immune response against the tumour. Importantly, iPSCs can be leveraged to develop off-the-shelf allogenic immunotherapy products.

conclusionThis article provides a comprehensive review of the application of iPSCs in tumor immunotherapy, along with a discussion of the opportunities and challenges in this evolving field.

Indexed as

ImmunotherapyImmunotherapy, AdoptiveInduced Pluripotent Stem CellsNeoplasmsAnimalsCancer VaccinesHumansCancer Vaccinesinduced pluripotent stem celliPSC-derived immune cellsiPSC-derived tumour vaccineopportunities and challengestumour immunotherapy

Identifiers

PMID40787691
PMCPMC12558626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.